Navigation Links
Vermillion Announces Appointment of John Hamilton to Board of Directors
Date:4/10/2008

FREMONT, Calif., April 10 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced the appointment of John F. Hamilton to its board of directors. Mr. Hamilton is the former vice president and chief financial officer of Depomed, Inc., a specialty pharmaceutical company.

"John brings more than 20 years of active board-level engagement on financial, strategic and audit matters to Vermillion. His solid experience working with small to mid-size companies in the healthcare sector is a perfect fit with our business model," said Gail Page, President and CEO of Vermillion. "We are pleased to welcome John to the board, especially at such an exciting time in the company's evolution as we prepare to commercialize several of our diagnostic tests later this year. His financial savvy and analytical approach will prove invaluable to the Company."

Mr. Hamilton began his career in the banking industry and went on to hold senior financial positions at several biopharmaceutical companies including Glyko, Inc. -- now BioMarin Pharmaceuticals -- and Chiron Corporation. He sits on the regional board of directors of the Association of Bioscience Financial Officers and is past-president of the Treasurers Club of San Francisco. Mr. Hamilton received his M.B.A. from the University of Chicago and his B.A. in International Relations from the University of Pennsylvania.

Mr. Hamilton's appointment to Vermillion's board of directors went into effect on April 9, 2008. Additionally, Mr. Hamilton will serve as chairman of the Company's audit committee. He will replace Judy Bruner, executive vice president of administration and chief financial officer of SanDisk Corporation, who resigned from the board
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
2. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
3. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
4. Vermillion Announces Effectiveness of Reverse Stock Split
5. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
8. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
9. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
10. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
11. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Calif. , July 24, 2014 SRI ... contract with the National Institute of Allergy and Infectious ... to conduct preclinical development of potential therapies for HIV ... drugs to treat HIV and AIDS and the complications ... as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... 24, 2014 WIRB-Copernicus Group ® ... ethical review services for clinical research, announced today ... division of Richmond, VA -based ... and biosecurity consulting firm in the ... biosafety division – WCG Biosafety™ – will be ...
(Date:7/24/2014)... 24, 2014   Cypher Genomics, Inc., ... of Adam Simpson as president and ... and comprehensive annotation and interpretation of individual human ... "Cypher,s technology has the potential to play ... diagnostic accuracy, optimizing therapeutic approaches and reducing adverse ...
(Date:7/23/2014)... Inc. (NASDAQ: SGMO ) today reported its ... For the second quarter ended June 30, 2014, ... or $0.10 per share, compared to a net loss ... same period in 2013. As of June 30, 2014, ... interest receivable of $236.7 million. Revenues for ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9
... Submission for Removal of Clinical Hold, BERKELEY ... Board: GNTA) announced that the Company has,received notice ... European,Patent Office for its pipeline product, tesetaxel, a ... matter for the tesetaxel drug,substance and to processes ...
... prion reduction technology to, further reduce risk of variant ... ... Octaplas(R), - Octapharma sponsoring lunchtime Symposium at meeting to discuss ... product quality., MONTREAL, Canada and CAMBRIDGE, United Kingdom, June 10,/PRNewswire-FirstCall/ ...
... Targets, COPENHAGEN, June 10 Nuevolution A/S ... (Nasdaq: LXRX ) aimed,at the discovery of ... targets., Under the terms of the alliance, ... to identify novel small molecule,lead compounds against a ...
Cached Biology Technology:Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 2Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 3Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 4ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 2ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 3ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 4ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 5ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 6Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals 2Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals 3
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... on different species of fish, according to a ... Exeter which tested fish anti-predator behaviour. , ... predator model when exposed to additional noise, whereas ... , Lead author Dr Irene Voellmy of Bristol,s ... many aquatic environments have increased substantially during the ...
(Date:7/24/2014)... its own microbial terroir, meaning the microbial populations found ... the product, creating the final flavor according to research ... and Environmental Microbiology . This is the first time ... brewery. , Many sake makers inoculate with both ... of the University of California, Davis, but he and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4The microbes make the sake brewery 2
... 2010) -- Drug delivery inside the body is a ... solutions, lipid membranes, and barriers between the blood and ... Institute of Physics publication the Journal of Chemical ... the hydration free energy (HFE) of a wide variety ...
... (July 27, 2010) -- In biology and genetics, the concept ... more (or less) than the sum of its parts. The ... an organism has the potential to depend strongly upon the ... even other mutations co-occurring in that gene. These genetic interactions, ...
... punch tiny holes in the protective membranes of cells, ... small molecules, proteins and DNA directly into living cells. ... light trigger the tiny blasts, which open holes in ... contained in the surrounding fluid. By adjusting laser ...
Cached Biology News:Getting a step ahead of pathogens 2Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 2Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 3Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 4
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
... [EP282Y] to Asparagine synthetase ( ... applications). Antigen: ... residues in the C-terminus of ... Entrez GeneID: 440 ...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Biology Products: